Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 170
Appendix ~
Cbronology of Wont Events
Recoding Vaccine Sooty
Year
~~e
[icensure
Leg~lndon armor IBM Repods on
PoMcy Statements Vaccine Saw
1933
waved
Is
vaccine (IPV) avaU~le
1963 ~ as
vaccine (OPV)
_, Is ~
Measles vaccine allele
1967
1969
1971
1977
gums vaccine avaU~le
RubeUa vaccine av~l~le
easles-~u~s-RubeHa
(WAR) vaccine av~l~le
1979 Current ~rmuladon of
rubella vaccine av~l~le
replaces earlier versions
1982 Plasma-de~ved bep~ds B
. ·. . .
vane me
gums vaccination
recommended
7~
fo/~ffi~ ~~
OCR for page 171
APPENDIX C
171
Vaccine
Year Licensure
Legislation and/or
Policy Statements
IOM Reports on
Vaccine Safety
1985 Hib vaccine licensed for
children >15 months
1986
1988
1990
Congress passes Public
Law 99-660, the National
Childhood Vaccine
Injury Act (introduced
in 1984) calls for:
· est. of NVPO
· est. of NVAC
· est. of VICP
· est. of ACCV
IOM review of
1) pertussis and rubella,
2) routine child vaccines
2 Hib conjugate vaccines
licensed for use beginning
at 2 months
Evaluation of Poliomyelitis
Vaccine Policy Options
1991 Acellular pertussis Hepatitis B Adverse Effects of Pertussis
component licensed for the recommended by ACIP and Rubella Vaccines
4th and 5th doses of the for addition to
5-part DTP series in
ACEL-IMUNE
childhood immunization
schedule
ACIP recommends Hib
be added to childhood
immunization schedule
1992 Acellular pertussis Hepatitis B vaccine:
component licensed for the Added universal
4th and 5th doses of the vaccination for all
5-part DTP series in infants, high-risk
Tripedia adolescents (e.g., IV
drug users, persons with
multiple sex partners)
1993 Combined DTP and Hib
vaccine (Tetramune)
licensed
OCR for page 172
172
IMMUNIZATION SAFETY REVIEW
Vaccine
Year Licensure
Legislation and/or
Policy Statements
IOM Reports on
Vaccine Safety
1994
1995
1996
Varicella virus vaccine
available (Varivax)
DTaP vaccine licensed for
first three doses given in
infancy (Tripedia and
ACEL-IMUNE were
ACIP recommends
using IPV for the first
2 polio vaccinations,
followed by OPV for
previously licensed for only remaining doses.
the 4th and 5th doses). Intended to be a
transitional schedule for
3-5 years until an
all-IPV series is available
ACIP recommends
children 12months-
12 years receive
Varicella vaccine
1997 Additional DTaP vaccine ACIP recommends
(Infanrix) licensed for first DTaP in place of DTP
4 doses of 5-part series
1998 Additional DTaP vaccine
(Certiva) licensed for first
4 doses of 5-part series
Adverse Events Associated
with Childhood Vaccines:
Evidence Bearing on
Causality
DPT and Chronic Nervous
System Dysfunction: A
New Analysis
Options for Poliomyelitis
Vaccinations in the United
States: Workshop Summary
Vaccine Safety Forum:
Summary of Two
Workshops
Risk Communication and
Vaccination: Workshop
Summary
ACIP updates MMR
recommendation,
encouraging use of the
combined MMR vaccine
OCR for page 173
APPENDIX C
173
Vaccine
Year Licensure
Legislation and/or
Policy Statements
IOM Reports on
Vaccine Safety
1999
2000
2001
Additional supply of
thimerosal-free hepatitis
B vaccine made available
Pneumococcal vaccine
for infants and young
children licensed (Prevnar)
ACIP updates varicella
vaccine recommendation,
requiring immunity for
child care and school entry
ACIP recommends an
all-IPV schedule begin
January 2000 to prevent
cases of vaccine-associated
paralytic polio
AAP and PHS recommend
removal of thimerosal
from vaccines
Also recommended
postponement of hepatitis
B vaccine from birth to
2-6 months for infants
of hepatitis B surface
antigen-negative mothers
MMWR notifies readers
of the availability of a
thimerosal-free hepatitis
B vaccine, enabling the
resumption of the birth
dose
ACIP recommends
pneumococcal
vaccination for all
children 2-23 months,
and at-risk children
24-59 months (e.g.,
immunocompromised)
October: ACIP drafts
statement expressing a
preference for use of
thimerosal-free DTaP,
Hib, and Hep B vaccines
by March 2002
Immunization Safety
Review: Measles-Mumps-
Rubella Vaccine and
Autism
Immunization Safety
Review: Thimerosal-
Containing Vaccines and
Neuro-developmental
Disorders
OCR for page 174
174
IMMUNIZATION SAFETY REVIEW
Vaccine
Year Licensure
Legislation and/or
Policy Statements
IOM Reports on
Vaccine Safety
2002
Immunization Safety
Review: Multiple
Immunizations and Immune
Dysfunction
Immunization Safety
Review: Hepatitis B
Vaccine and Demyelinating
Neurological Disorders
Immunization Safety
Review: SV40
Contamination of Polio
Vaccine and Cancer
2003 Live attenuated intranasal ACIP recommends Immunization Safety
influenza vaccine that children 6 to Review: Hepatitis B
approved for use in the 23 months of age be Vaccine and Demyelinating
United States in healthy vaccinated annually Neurological Disorders
individuals aged against influenza
5-49 years old (FluMist) beginning in the Immunization Safety
2004-2005 influenza Review: SV40
season Contamination of Polio
Vaccine and Cancer
Immunization Safety
Review: Vaccinations and
Sudden Unexpected Death
in Infancy
l
Representative terms from entire chapter:
acip recommends
